Vaccine最新文献

{"title":"Australian parents' experiences with adolescent age-based vaccinations during the COVID-19 pandemic","authors":"Maryke S. Steffens ,&nbsp;Katarzyna T. Bolsewicz ,&nbsp;Catherine King ,&nbsp;Bianca Bullivant ,&nbsp;Ikram Abdi ,&nbsp;Frank Beard","doi":"10.1016/j.vaccine.2024.126498","DOIUrl":"10.1016/j.vaccine.2024.126498","url":null,"abstract":"<div><h3>Purpose</h3><div>In Australia, adolescents are scheduled to receive vaccinations against diphtheria, tetanus, pertussis, human papillomavirus, and meningococcal disease, delivered via school vaccination programs and general practitioners (GPs). Public health measures implemented in response to the COVID-19 pandemic impacted uptake of some adolescent age-based vaccinations. Limited information is available on parents' approaches to vaccinating their adolescent children during the pandemic. We aimed to explore parents' experiences of adolescent age-based vaccinations during the pandemic, and factors they perceived as hindering or facilitating vaccination.</div></div><div><h3>Methods</h3><div>In July 2022 we recruited 21 Australian parents of adolescent children eligible for age-based vaccinations in 2021. We recruited from metropolitan and regional settings, and from states where uptake was most and least affected by pandemic disruptions. We conducted 30-min virtual or phone interviews and analysed the data thematically.</div></div><div><h3>Results</h3><div>Parents described how experiences before and during the COVID-19 pandemic influenced their perspectives on and experiences with adolescent age-based vaccinations. Motivation to vaccinate their children was informed by personal beliefs and experiences with the healthcare system. Parents described practical issues, including ease of access to the school vaccination program or a GP, and knowledge about vaccination schedules and services. Parents suggested enhancing promotion of adolescent vaccination benefits and information sharing, and recommended improving access to vaccination services outside the school program.</div></div><div><h3>Discussion</h3><div>Findings have potential to improve delivery of adolescent age-based vaccinations, including during future pandemics. While this study was conducted in the Australian context, findings and recommendations have relevance to overseas adolescent age-based vaccination programs.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126498"},"PeriodicalIF":4.5,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study","authors":"Sung-a Kim ,&nbsp;Megumi Maeda ,&nbsp;Fumiko Murata ,&nbsp;Haruhisa Fukuda","doi":"10.1016/j.vaccine.2024.126497","DOIUrl":"10.1016/j.vaccine.2024.126497","url":null,"abstract":"<div><h3>Introduction</h3><div>Post-COVID-19 conditions have emerged as a global health challenge. This study examined the long-term effects of COVID-19 vaccination on the incidence and risk of post-COVID-19 conditions in Japan.</div></div><div><h3>Methods</h3><div>This retrospective cohort study was conducted using a database comprising medical claims, COVID-19 case information, and vaccination records of persons residing in four Japanese municipalities. The cohort included COVID-19 cases diagnosed between August 2020 and December 2022. Participants were classified according to the duration between their most recent COVID-19 vaccination and COVID-19 occurrence (≥365 days, 150–364 days, and 14–149 days). The incidences of 36 post-COVID-19 conditions were monitored for 3, 5, and 8 months after infection. Cox proportional hazards models were used to calculate the risk of developing each post-COVID-19 condition within 8 months after infection according to vaccination status.</div></div><div><h3>Results</h3><div>From among 84,464 participants, 9642 (11.4 %) developed post-COVID-19 conditions over 8 months. The 8-month risks of developing 28 (including various respiratory conditions, cardiovascular conditions, inflammatory and immune diseases, physical conditions, psychiatric conditions, and endocrine disorders) of the 36 target conditions were significantly lower when individuals had been recently vaccinated (14–149 days) before infection.</div></div><div><h3>Conclusions</h3><div>COVID-19 vaccination can reduce the incidence and risk of post-COVID-19 conditions if administered within 5 months before infection. Despite having the highest mean age and prevalence of comorbidities, individuals who were most recently vaccinated had a lower risk of developing post-COVID-19 conditions. These results provide important evidence for future COVID-19 vaccination strategies.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126497"},"PeriodicalIF":4.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of preventive practices","authors":"K. Delaruelle ,&nbsp;E. Lermytte ,&nbsp;M. Bockstal ,&nbsp;P. Vuolanto ,&nbsp;P. Bracke","doi":"10.1016/j.vaccine.2024.126485","DOIUrl":"10.1016/j.vaccine.2024.126485","url":null,"abstract":"<div><h3>Background</h3><div>The COVID-19 pandemic underscored the issue of vaccine hesitancy, leading researchers to study the determinants of people's willingness to receive the COVID-19 vaccine. This study is the first to comprehensively investigate the role of preventive practices at both the individual and contextual level, drawing on the theoretical concept of “cultural health capital”.</div></div><div><h3>Methods</h3><div>Utilizing data from the Survey of Health, Ageing, and Retirement (SHARE), covering information from 18,454 individuals aged 50 years and above residing in 25 European countries, we examined the influence of past engagement in preventive practices and the prevalence of such practices within a country on the likelihood of COVID-19 vaccine uptake. Our analysis included (i) previous vaccination behaviors, (ii) other healthcare-related behaviors, and (iii) lifestyle factors at both the individual and contextual levels. Leveraging the longitudinal design of the SHARE, we accounted for the temporal ordering of the relationships.</div></div><div><h3>Results</h3><div>At the individual level, almost all preventive behaviors were significantly related to people's willingness to receive the COVID-19 vaccine. Individuals who (i) had received an influenza vaccination prior to the COVID-19 outbreak and during childhood, (ii) had regularly participated in dental and blood pressure check-ups throughout their lives, and (iii) did not engage in lifestyle-related risk behaviors, were more likely to accept the COVID-19 vaccine. Notably, alcohol use was not significantly associated. At the contextual level, only the vaccination coverage rate for influenza was found to be robustly related, indicating that individuals were more inclined to receive the COVID-19 vaccine in countries with higher influenza vaccination rates prior to the pandemic.</div></div><div><h3>Conclusion</h3><div>Active participation in preventive practices and effective implementation of vaccination campaigns can contribute to the development of (institutional) cultural health capital, which ultimately promotes a greater willingness to get vaccinated against COVID-19.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126485"},"PeriodicalIF":4.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection” [Vaccine 42 (1–12) (2024) 126325]","authors":"Susan D. Kerfua ,&nbsp;Daniel T. Haydon ,&nbsp;Ginette Wilsden ,&nbsp;Anna Ludi ,&nbsp;Donald P. King ,&nbsp;Rose Ademun Okurut ,&nbsp;Stella Atim ,&nbsp;Moses T. Dhikusooka ,&nbsp;Ivan Kyakuwa ,&nbsp;Paolo Motta ,&nbsp;David J. Paton","doi":"10.1016/j.vaccine.2024.126480","DOIUrl":"10.1016/j.vaccine.2024.126480","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126480"},"PeriodicalIF":4.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost effectiveness analysis of rotavirus vaccination in Indonesia","authors":"Jarir At Thobari ,&nbsp;Emma Watts ,&nbsp;Natalie Carvalho ,&nbsp;Jonathan Hasian Haposan ,&nbsp;Andrew Clark ,&nbsp;Frédéric Debellut ,&nbsp;Asal Wahyuni Erlin Mulyadi ,&nbsp;Julitasari Sundoro ,&nbsp;Mardiati Nadjib ,&nbsp;Sri Redzeki Hadinegoro ,&nbsp;Julie Bines ,&nbsp;Yati Soenarto","doi":"10.1016/j.vaccine.2024.126478","DOIUrl":"10.1016/j.vaccine.2024.126478","url":null,"abstract":"<div><h3>Background</h3><div>Rotavirus (RV) remains the most common cause of morbidity and mortality due to acute gastroenteritis (AGE) in children under five. In Indonesia, RV is responsible for 60 % of severe AGE and 40 % of non-severe AGE in these children. This study assessed the cost-effectiveness of introduction of rotavirus vaccines (RVV) into the National Immunization Program in Indonesia.</div></div><div><h3>Methods</h3><div>We conducted a cost-effectiveness analysis (CEA) of RVV introduction in Indonesia, assuming a three-dose vaccine schedule based on the planned introduction proposed by the Strategic Advisory Group of Experts on Immunization. The analysis involved an initial introduction of an imported RVV (Rotavac®, Bharat Biotech, India) followed by a staged implementation of the locally produced RVV (Bio Farma, Indonesia) from both health system and societal perspectives. The primary outcome measure was the incremental cost (2019 USD) per disability-adjusted life year (DALY) averted, compared to no vaccination. We took model inputs from an Indonesian cost-of-illness study, national information systems and scientific literature, covering disease incidence, hospitalization, mortality, healthcare costs, and vaccine related factors. Our analyses included univariate and probabilitistic sensitivity analyses to assess various parameters.</div></div><div><h3>Findings</h3><div>The cost of a 10-year vaccination program is 82.6 million USD and can potentially prevent 7.3 million cases of rotavirus and 0.42 million DALYs. From a societal perspective, the incremental cost-effectiveness ratio (ICER) for the staged program is 464 USD per DALY averted (12 % of Indonesia's gross domestic product (GDP) per capita). From a healthcare sector perspective, ICER is similar at 479 USD (13 % GDP per capita).</div></div><div><h3>Interpretation</h3><div>The introduction of RVV into the National Immunization Program is likely to be highly cost-effective in Indonesia.</div></div><div><h3>Funding</h3><div>This work was supported by funding agreement with the Murdoch Children's Research Institute (MCRI), PATH, and the Indonesian Technical Advisory Group on Immunization (ITAGI).</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126478"},"PeriodicalIF":4.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-level determinants of timely routine childhood vaccinations in The Gambia: Findings from a nationwide analysis","authors":"Oghenebrume Wariri ,&nbsp;Chigozie Edson Utazi ,&nbsp;Uduak Okomo ,&nbsp;Winfred Dotse-Gborgbortsi ,&nbsp;Malick Sogur ,&nbsp;Sidat Fofana ,&nbsp;Kris A. Murray ,&nbsp;Chris Grundy ,&nbsp;Beate Kampmann","doi":"10.1016/j.vaccine.2024.126500","DOIUrl":"10.1016/j.vaccine.2024.126500","url":null,"abstract":"<div><h3>Introduction</h3><div>Achieving the ambitious goals of the Immunisation Agenda 2030 (IA2030) requires a deeper understanding of factors influencing under-vaccination, including timely vaccination. This study investigates the demand- and supply-side determinants influencing the timely uptake of key childhood vaccines scheduled throughout the first year of life in The Gambia.</div></div><div><h3>Methods</h3><div>We used two nationally-representative datasets: the 2019–20 Gambian Demographic and Health Survey and the 2019 national immunisation facility mapping. Using Bayesian multi-level binary logistic regression models, we identified key factors significantly associated with timely vaccination for five key vaccines: birth dose of hepatitis-B (HepB0), first, second, and third doses of the pentavalent vaccine (Penta1, Penta2, Penta3), and first-dose of measles-containing vaccine (MCV1) in children aged 12–35 months. We report the adjusted Odds Ratios (aORs) and 95 % Credible Intervals (95 % CIs) in each case.</div></div><div><h3>Results</h3><div>We found that demand-side factors, such as ethnicity, household wealth status, maternal education, maternal parity, and the duration of the household's residency in its current location, were the most common drivers of timely childhood vaccination. However, supply-side factors such as travel time to the nearest immunisation clinic, availability of cold-storage and staffing numbers in the nearest immunisation clinic were also significant determinants. Furthermore, the determinants varied across specific vaccines and the timing of doses. For example, delivery in a health facility (aOR = 1.58, 95 %CI: 1.02–2.53), living less than 30 min (aOR = 2.11, 95 %CI: 1.2–8.84) and living between 30 and 60 min (aOR = 3.68, 95 %CI: 1.1–14.99) from a fixed-immunisation clinic was associated with timely HepB0, a time-sensitive vaccine that must be administered within 24 h of birth. On the other hand, children who received Penta1 and Penta2 on time were three- to five-fold more likely to receive subsequent doses on time (Penta2 and Penta3, respectively). Finally, proximity to an immunisation facility with functional vaccine cold-storage was a significant supply-side determinant of timely MCV1 (aOR = 1.4, 95 %CI: 1.09–1.99).</div></div><div><h3>Conclusions</h3><div>These findings provide valuable insights for programme managers and policymakers. By prioritising interventions and allocating scarce resources based on these identified determinants, they can maximize their impact and ensure children in The Gambia receive timely vaccinations throughout their first year of life, contributing to IA2030 goals.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126500"},"PeriodicalIF":4.5,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada","authors":"Katia Charland ,&nbsp;Caroline Quach ,&nbsp;Jesse Papenburg ,&nbsp;Laura Pierce ,&nbsp;Cat Tuong Nguyen ,&nbsp;Adrien Saucier ,&nbsp;Margot Barbosa Da Torre ,&nbsp;Marie-Ève Hamelin ,&nbsp;Julie Carbonneau ,&nbsp;Guy Boivin ,&nbsp;Kate Zinszer","doi":"10.1016/j.vaccine.2024.126489","DOIUrl":"10.1016/j.vaccine.2024.126489","url":null,"abstract":"<div><h3>Background</h3><div>Given the growing evidence on the benefits of hybrid immunity, continued monitoring of vaccine uptake is warranted, particularly of socio-demographic subgroups with early vaccine hesitancy. Racial/ethnic and lower income groups experienced a high infection incidence, but few studies account for the child's history of SARS-CoV-2 infection on the parent's decision to vaccinate their child.</div></div><div><h3>Methods</h3><div>EnCORE is a SARS-CoV-2 pediatric cohort study comprising five rounds of data collection from 2020 to 2023, with parental questionnaires at each round. Parent's responses on their intention to vaccinate their child and their reasons were summarized descriptively. Vaccine uptake was estimated through time and in relation to participant characteristics, using multivariable regression to adjust for covariates including a history of PCR/serology-confirmed SARS-CoV-2 infection prior to vaccine eligibility. At study end, we estimated the average time lapsed from last vaccine dose.</div></div><div><h3>Results</h3><div>The samples for vaccine uptake and intention to vaccinate analyses were 631 and 1137 participants, respectively. At study end, uptake was 88 % but approximately 49 % of 2-to-4-year-olds remained unvaccinated (95 % CI 39.0, 58.1) and for vaccinated participants the median time since last vaccination was 353 days. In regression analyses, after adjusting for infection prior to vaccine eligibility and other covariates, we found approximately a two-fold increase in unvaccinated status associated with the parent's identification as a racial/ethnic minority and with household income in the lowest sample tercile (minority: adjusted relative risk [aRR] 2.45, 95 % CI 1.56, 3.86; income: aRR 1.76, 95 % CI 1.17, 2.66).</div></div><div><h3>Conclusion</h3><div>By mid-2023, most participants were not protected by vaccine-induced antibodies, because they were unvaccinated or several months had lapsed from their last dose. A COVID-19 infection prior to vaccine eligibility was associated with a greater risk of remaining unvaccinated but did not fully account for low uptake in ethnic/racial minorities and lower income groups.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126489"},"PeriodicalIF":4.5,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Lassa fever disease in pregnant women and children and options for prevention","authors":"Manu Chaudhary ,&nbsp;Clare L. Cutland ,&nbsp;Mercedes Bonet ,&nbsp;Angela Gentile ,&nbsp;Christine E. Jones ,&nbsp;Helen S. Marshall ,&nbsp;Andy Stergachis ,&nbsp;Gerald Voss ,&nbsp;Delese Mimi Darko ,&nbsp;Esperanca Sevene ,&nbsp;Terri Hyde ,&nbsp;Lee Fairlie ,&nbsp;Beate Kampmann ,&nbsp;Darcie Everett ,&nbsp;Flor M. Munoz","doi":"10.1016/j.vaccine.2024.126479","DOIUrl":"10.1016/j.vaccine.2024.126479","url":null,"abstract":"<div><div>Lassa fever is a serious epidemic viral disease in West Africa affecting an estimated 2 million people annually with about 5000–10,000 deaths, although supporting data is sparse. Lassa fever significantly affects neonates, children, and pregnant women, however, comprehensive data on its impact in these populations are lacking. We reviewed the available literature on Lassa fever to assess its prevalence and impact in these populations and implications for vaccine development. Clinical features in children were similar to those observed in adults, with complications such as bleeding. Altered mental status, anasarca (swollen baby syndrome), bleeding, and poor urine output were risk factors for death. The case fatality rate (CFR) in 16 paediatric studies ranged from 6 % to 63 % and was 66.7 % and 75.0 % in two neonatal studies. In a systematic review of studies on pregnant women the CFR was 33.73 %. The adverse foetal outcomes included miscarriage, stillbirth, and intrauterine death associated with maternal death. Since Lassa fever significantly affects neonates, children, and pregnant women, developing a safe and effective, single-dose vaccine for these high-risk populations is vital. Currently, there are four clinical trials assessing Lassa virus vaccines. Only one of these trials is enrolling children aged ≥18 months, and exclude pregnant and breast-feeding women. It is essential that pregnant and breast-feeding women and young children are included in clinical trials that incorporate robust safety surveillance and risk mitigation measures. In our review, potential approaches to address the specific gaps in the areas of diagnosis, management, and prevention of Lassa fever in these specific populations, such as disease surveillance systems and vaccine development, were identified. A comprehensive strategy with investment focused on addressing specific knowledge gaps will be essential in protecting the health of these specific populations in Lassa virus endemic regions.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126479"},"PeriodicalIF":4.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses","authors":"Aleda M. Leis ,&nbsp;Abram Wagner ,&nbsp;Brendan Flannery ,&nbsp;Jessie R. Chung ,&nbsp;Arnold S. Monto ,&nbsp;Emily T. Martin","doi":"10.1016/j.vaccine.2024.126493","DOIUrl":"10.1016/j.vaccine.2024.126493","url":null,"abstract":"<div><div>Test-negative design (TND) studies are cornerstones of vaccine effectiveness (VE) monitoring for influenza. The introduction of SARS-CoV-2 and RSV vaccines complicate the analysis of this design, with control selection restriction based on other pathogen diagnosis proposed as a solution. We conducted a simulation study and secondary analysis of 2017–18 and 2018–19 TND estimates from a Southeast Michigan ambulatory population to evaluate RSV-status-based control restriction. Simulations suggest that with vaccine-preventable RSV, influenza VE could be moderately biased with RSV prevalence ≥25 % of controls. Real-world analysis showed 151 influenza-negative adults (10.4 %) had RSV detected from the enrollment nasal swab. There were minimal differences in results of adjusted models with or without RSV exclusion from control groups. Findings suggest that inclusion of RSV cases in the control group of TND studies for influenza VE, particularly where RSV is not vaccine preventable, does not currently pose a major concern for bias in VE estimates.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126493"},"PeriodicalIF":4.5,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.","authors":"Reuben McGregor ,&nbsp;Aimee Paterson ,&nbsp;Brittany Lavender ,&nbsp;Caitlin Hooker ,&nbsp;Chris Frampton ,&nbsp;Kjesten Wiig ,&nbsp;Graham Le Gros ,&nbsp;James E. Ussher ,&nbsp;Maia Brewerton ,&nbsp;Nicole J. Moreland","doi":"10.1016/j.vaccine.2024.126482","DOIUrl":"10.1016/j.vaccine.2024.126482","url":null,"abstract":"<div><div>The successive dominance of SARS-CoV-2 omicron sublineages presents challenges for vaccination strategies with respect to the antigenic content of boosters. New Zealand's COVID-19 elimination strategy (2020−2021) ensured the major vaccination campaign (Pfizer-BioNTech BNT162b2) was completed pre-omicron in an infection-naive population, providing a unique setting to explore the impact of omicron infection waves on vaccine responses. This study compared neutralising antibodies (NAb) to eight SARS-CoV-2 omicron sublineages 28-days and 11-months after a third dose. Participants (<em>n</em> = 219) were classified by antigen exposure in the intervening 10 months including additional vaccinations and/or infections. Both vaccination and infection boosted NAb levels to all sublineages. Antigenic maps showed infection had a major impact on NAb breadth, despite all participants being vaccinated with an ancestral-based vaccine.</div><div>While vaccination remains an important tool to boost immunity, the breadth of NAbs observed suggest that attempts to match booster specificity with current circulating variants may not always be necessary.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126482"},"PeriodicalIF":4.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}